Last reviewed · How we verify
NCT03795779
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
EARLY_PHASE1 trial testing CLL1-CD33 cCAR T cells in Hematologic Malignancy in 20 participants. Status unknown.
30 September 2022
Quick facts
| Lead sponsor | iCell Gene Therapeutics |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 March 2018 |
| Primary completion | 30 September 2022 |
| Estimated completion | 30 September 2022 |
| Sites | 2 locations across China |
Drugs / interventions tested
- CLL1-CD33 cCAR T cells — full drug profile →
Conditions studied
- Hematologic Malignancy — all drugs for Hematologic Malignancy →
- Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
- Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →
- Myeloproliferative Neoplasm — all drugs for Myeloproliferative Neoplasm →
Sponsor
iCell Gene Therapeutics — full company profile →
Who can join
Eligibility, any sex, with Hematologic Malignancy or Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CLL1-CD33 cCAR in patients with relapsed and/or refractory, high risk hematologic malignancies.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.
Walcher L, Kistenmacher AK, Suo H, Kitte R, et al · · 2020 · cited 688× · PMID 32849491 · DOI 10.3389/fimmu.2020.01280 -
Emerging agents and regimens for AML.
Liu H. · · 2021 · cited 210× · PMID 33757574 · DOI 10.1186/s13045-021-01062-w -
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.
Daver N, Alotaibi AS, Bücklein V, Subklewe M. · · 2021 · cited 178× · PMID 33953290 · DOI 10.1038/s41375-021-01253-x -
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions.
Mardiana S, Gill S. · · 2020 · cited 155× · PMID 32435621 · DOI 10.3389/fonc.2020.00697 -
Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis.
Yamashita M, Dellorusso PV, Olson OC, Passegué E. · · 2020 · cited 128× · PMID 32415283 · DOI 10.1038/s41568-020-0260-3 -
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.
Daver NG, Maiti A, Kadia TM, Vyas P, et al · · 2022 · cited 126× · PMID 36218325 · DOI 10.1158/2159-8290.cd-22-0332 -
Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance.
Alves R, Gonçalves AC, Rutella S, Almeida AM, et al · · 2021 · cited 112× · PMID 34638304 · DOI 10.3390/cancers13194820 -
CAR-T cell therapy for cancer: current challenges and future directions.
Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, et al · · 2025 · cited 81× · PMID 40610404 · DOI 10.1038/s41392-025-02269-w
Verify or expand the search:
- PubMed search for NCT03795779
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hematologic Malignancy
Currently open trials in the same condition.
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT07511127 — Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT · Phase 3 · recruiting
- NCT07413991 — Expressive Writing Program Among Young Adults With Blood Cancer · NA · active not recruiting
- NCT06487247 — HEME Home Transfusion Program · NA · recruiting
- NCT07035938 — T-cell Developmental Status in Patients With Malignant Hematological Tumors · recruiting
Other iCell Gene Therapeutics trials
Trials by the same sponsor.
- NCT05445765 — Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia · Phase 1 · unknown
- NCT05212584 — CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma · Phase 1 · unknown
- NCT05474885 — BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE) · Phase 1 · unknown
- NCT04594135 — Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies · Phase 1 · unknown
- NCT04934774 — Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03795779 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by iCell Gene Therapeutics
- Last refreshed: 19 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03795779.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing